In the REAL8 basket trial, Sogroya (somapacitan), administered as a once-weekly subcutaneous injection, was at least as ...

The Danish multinational said that Sogroya improved the yearly growth rate in pre-pubertal children born small for ...

With a late-stage trial win for its Norditropin heir in hand, Novo Nordisk is making good on plans to boost its profile in ...

Lilly said it would seek approval from the ... intense efforts by scientists to make an insulin pill. So is human growth hormone. So are drugs used to treat a wide variety of diseases, including ...

Eli Lilly has lined up another deal in the ... Novo Nordisk's long-acting growth hormone Sogroya works as well as Norditropin in a trio of paediatric growth disorders, with far fewer injections.

In addition to diabetes drugs, the company also makes drug treatments for wound healing, menopausal hormone replacement, and human growth hormone ... offerings from Eli Lilly and other rivals ...

Pharmacy stocks, including Eli Lilly (LLY), Johnson & Johnson ... the launch of a next-generation digital ecosystem for Growth Hormone Deficiency, a move that underscores its commitment to ...

Pharmacy stocks, including Eli Lilly (LLY), Johnson & Johnson (JNJ), and Merck ... recently announced the launch of a next-generation digital ecosystem for Growth Hormone Deficiency, a move that ...